Using PSMA-1007 Imaging for Staging Prostate Cancer
The Clinical Impact and Prognostic Value of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer: Real-world Evidence From a Monocentric, Prospective Observational Study
This study is testing a new imaging method called PSMA-1007 to see if it can better detect prostate cancer and its spread to lymph nodes compared to standard imaging techniques.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Heinrich-Heine University, Duesseldorf Academic / other |
| Locations | 1 site (Düsseldorf, North Rhine-Westphalia) |
| Trial ID | NCT06820333 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of [18F] PSMA-1007 imaging in the primary staging of prostate cancer in real-world clinical settings. It will collect data on the diagnostic accuracy of this imaging technique compared to traditional methods, focusing on its ability to detect pelvic lymph node involvement. The study will involve a diverse patient population and will address limitations found in previous studies by allowing for long-term observation and a larger sample size. The goal is to generate evidence-based insights that can enhance the management of prostate cancer.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are scheduled for a first diagnosis of prostate cancer and can provide informed consent.
Not a fit: Patients with imaging artifacts that limit the assessability of the examinations will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment planning for patients with prostate cancer.
How similar studies have performed: Previous studies have shown promising results for PSMA imaging, indicating a potential for success in this novel real-world evidence approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> 18 years * Planned \[18F\]PSMA-1007 PET/CT examination in patients with a first diagnosis of prostate cancer * Informed consent Exclusion Criteria: \- Examinations with limited assessability due to technical errors, such as imaging artifacts.
Where this trial is running
Düsseldorf, North Rhine-Westphalia
- Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf — Düsseldorf, North Rhine-Westphalia, Germany (Recruiting)
Study contacts
- Study coordinator: Emil Novruzov, Medical Doctor
- Email: Emil.Novruzov@med.uni-duesseldorf.de
- Phone: (+49)211 8118540
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.